Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

R-CVP regimen

View Patient Information

A regimen consisting of cyclophosphamide, vincristine, prednisone (CVP) and rituximab that may be used in the treatment of some forms of non-Hodgkin's lymphoma (NHL), including follicular lymphoma, gastric and nongastric MALT lymphomas, nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL), Castleman disease and post-transplant lymphoproliferative disorders.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	CVP-rituximab CVP/rituximab cyclophosphamide/prednisone/rituximab/vincristine cyclophosphamide/vincristine/prednisone/rituximab rituximab-cyclophosphamide-vincristine-prednisone regimen

R-CVP regimen

Search NCI's Drug Dictionary